Terms: = Thyroid cancer AND CgA AND Prognosis
20 results:
1. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological Features of Intrathyroid Thymic Carcinoma].
Zheng ZG; Sun WY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Feb; 43(1):42-46. PubMed ID: 33663661
[TBL] [Abstract] [Full Text] [Related]
3. Parathyroid carcinoma with sarcomatoid differentiation: a case report and literature review.
Hu L; Xie X
Diagn Pathol; 2020 Dec; 15(1):142. PubMed ID: 33317559
[TBL] [Abstract] [Full Text] [Related]
4. [Primary carcinoid of ovary: a clinicopathologic analysis of 17 cases].
Zhu R; Xue XW; Luo YF; Wu HW; Huo Z
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):339-343. PubMed ID: 29783799
[No Abstract] [Full Text] [Related]
5. Clinicopathological features of low-grade malignant endolymphatic sac tumors.
Wang HQ; Jie L; Shi HY
Pathol Res Pract; 2018 Mar; 214(3):431-435. PubMed ID: 29482989
[TBL] [Abstract] [Full Text] [Related]
6. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
[TBL] [Abstract] [Full Text] [Related]
8. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases.
Li JD; Zhuang Y; Li YF; Feng YL; Hou JH; Chen L; Zhu AN; Wu QL; Yun JP
J Clin Pathol; 2011 Dec; 64(12):1102-7. PubMed ID: 21965825
[TBL] [Abstract] [Full Text] [Related]
9. Malignant mesenchymoma of the thyroid: case report and literature review.
Shi H; Wang C; Wei L; Lu S; Cao D
Tumori; 2010; 96(2):345-8. PubMed ID: 20572598
[TBL] [Abstract] [Full Text] [Related]
10. The surgical strategy and the molecular analysis of patients with parathyroid cancer.
Enomoto K; Uchino S; Ito A; Watanabe S; Shibuya H; Enomoto Y; Noguchi S
World J Surg; 2010 Nov; 34(11):2604-10. PubMed ID: 20480190
[TBL] [Abstract] [Full Text] [Related]
11. [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix].
Deng GH; Zhang X; Wu LY
Zhonghua Zhong Liu Za Zhi; 2010 Mar; 32(3):199-202. PubMed ID: 20450588
[TBL] [Abstract] [Full Text] [Related]
12. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases.
Lu J; Xue LY; Lu N; Zou SM; Liu XY; Wen P
Dis Esophagus; 2010 Feb; 23(2):153-9. PubMed ID: 19515193
[TBL] [Abstract] [Full Text] [Related]
13. Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution.
Alijo Serrano F; Sánchez-Mora N; Angel Arranz J; Hernández C; Alvarez-Fernández E
Am J Clin Pathol; 2007 Nov; 128(5):733-9. PubMed ID: 17951193
[TBL] [Abstract] [Full Text] [Related]
14. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases.
Yun JP; Zhang MF; Hou JH; Tian QH; Fu J; Liang XM; Wu QL; Rong TH
BMC Cancer; 2007 Mar; 7():38. PubMed ID: 17335582
[TBL] [Abstract] [Full Text] [Related]
15. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
[TBL] [Abstract] [Full Text] [Related]
16. Chromogranin A measurement in neuroendocrine tumors.
Ferrari L; Seregni E; Martinetti A; Van Graafeiland B; Nerini-Molteni S; Botti C; Artale S; Cresta S; Bombardieri E
Int J Biol Markers; 1998; 13(1):3-9. PubMed ID: 9681293
[TBL] [Abstract] [Full Text] [Related]
17. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract] [Full Text] [Related]
18. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract] [Full Text] [Related]
19. p53 gene mutation in thyroid carcinoma.
Ho YS; Tseng SC; Chin TY; Hsieh LL; Lin JD
Cancer Lett; 1996 May; 103(1):57-63. PubMed ID: 8616809
[TBL] [Abstract] [Full Text] [Related]
20. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
[TBL] [Abstract] [Full Text] [Related]
